Skip to main content
Erschienen in: Virchows Archiv 4/2013

01.10.2013 | Original Article

Mixed low- and high-grade papillary urothelial carcinoma: histopathogenetic and clinical significance

verfasst von: Kien T. Mai, Trevor A. Flood, Phillip Williams, Zuzana Kos, Eric C. Belanger

Erschienen in: Virchows Archiv | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

There are two pathways of urothelial carcinogenesis: low-grade urothelial carcinoma (LGUC) with low rates of gene alterations and high-grade urothelial carcinoma (HGUC) with numerous gene alterations. HGUC often displays strong reactivity for cytokeratin 20 (CK20) and p16. Despite distinct molecular changes, urothelial carcinoma (UC) with both low- and high-grade features is not uncommon. We examined cases with patterns of mixed low- and high-grade UC (MLHGUC). Consecutive cases of UC at our institution were reviewed. There were 45 cases that showed a mixture of both LGUC and HGUC. IHC for CK5, CK20, CD44, p16, and Ki67 was performed. Areas of HGUC displayed strong and diffuse reactivity for p16, CK20, and Ki67 in 20–50 % of the tumor, while LGUC areas had negative or focal reactivity for CK20 and Ki67 in 10–30 %. There were two distinct cohorts of MLHGUC: patients with a history of LGUC (group A) and those without (group B). Group A patients (n = 8) had a history of LGUC for 1–10 years. The tumor specimens weighed 1.5 ± 1.7 g and had HGUC components of 25 ± 20 % of the tissue. Superficial invasion was present in one case. All tumors had BCG treatment with one recurrence. In group B (n = 37), tumor specimens weighed 3 ± 3.9 g and had HGUC components in 43 ± 21 % of the tissue. Superficial invasion was present in five cases, and muscle invasion with lung metastasis occurred in one case. Four cases were refractory to BCG with an increased proportion of HGUC, and one case requiring cystectomy. Differences in size and proportion of HGUC between groups A and B MLHGUC were significant (P < 0.05), with group B presenting with a higher tumor burden and proportion of HGUC. MLHGUC is diagnostically challenging and is commonly assigned high grade since this determines prognosis. Group A MLHGUC likely develops as a result of progression from LGUC, whereas group B MLHGUC likely develops de novo, is associated with larger tumors, shows a higher proportion of HGUC, and follows a worse prognosis. Despite the similar histology of groups A and B, assignment to HGUC in a binary system may mask important prognostic information.
Literatur
1.
2.
Zurück zum Zitat Eble JN, Young RH (1997) Carcinoma of the urinary bladder: a review of its diverse morphology. Semin Diagn Pathol 14:98–108PubMed Eble JN, Young RH (1997) Carcinoma of the urinary bladder: a review of its diverse morphology. Semin Diagn Pathol 14:98–108PubMed
4.
Zurück zum Zitat Pan CC, Chang YH, Chen KK, Yu HJ, Sun CH, Ho DM (2010) Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515. Am J Clin Pathol 133(5):788–95PubMedCrossRef Pan CC, Chang YH, Chen KK, Yu HJ, Sun CH, Ho DM (2010) Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515. Am J Clin Pathol 133(5):788–95PubMedCrossRef
5.
Zurück zum Zitat Eble JN, Sauter G, Epstein JI et al (eds) (2004) World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs. IARC, Lyon Eble JN, Sauter G, Epstein JI et al (eds) (2004) World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs. IARC, Lyon
6.
Zurück zum Zitat Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ, Epstein JI (2010) Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int 60(2):147CrossRef Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ, Epstein JI (2010) Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int 60(2):147CrossRef
7.
Zurück zum Zitat Yin H, Leong AS (2004) Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up. Am J Clin Pathol 121(5):679–87PubMedCrossRef Yin H, Leong AS (2004) Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up. Am J Clin Pathol 121(5):679–87PubMedCrossRef
8.
Zurück zum Zitat Bircan S, Candir O, Serel TA (2004) Comparison of WHO 1973, WHO/ISUP 1998, WHO 1999 grade and combined scoring systems in evaluation of bladder carcinoma. Urol Int 73(3):201–8PubMedCrossRef Bircan S, Candir O, Serel TA (2004) Comparison of WHO 1973, WHO/ISUP 1998, WHO 1999 grade and combined scoring systems in evaluation of bladder carcinoma. Urol Int 73(3):201–8PubMedCrossRef
9.
Zurück zum Zitat Miyamoto H, Brimo F, Schultz L, Ye H, Miller JS, Fajardo DA, Lee TK, Epstein JI, Netto GJ (2010) Low-grade papillary urothelial carcinoma of the urinary bladder: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center. Arch Pathol Lab Med 134(8):1160–3. doi:10.1043/2009-0403-OA.1 PubMed Miyamoto H, Brimo F, Schultz L, Ye H, Miller JS, Fajardo DA, Lee TK, Epstein JI, Netto GJ (2010) Low-grade papillary urothelial carcinoma of the urinary bladder: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center. Arch Pathol Lab Med 134(8):1160–3. doi:10.​1043/​2009-0403-OA.​1 PubMed
10.
Zurück zum Zitat Jalalinadoushan M, Peivareh H, Azizzadeh Delshad A (2004) Correlation between apoptosis and histological grade of transitional cell carcinoma of urinary bladder. Urol J 1(3):177–9PubMed Jalalinadoushan M, Peivareh H, Azizzadeh Delshad A (2004) Correlation between apoptosis and histological grade of transitional cell carcinoma of urinary bladder. Urol J 1(3):177–9PubMed
11.
Zurück zum Zitat Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C (2010) Molecular pathways of urothelial development and bladder tumorigenesis. Urologic Oncology: Seminars and Original Investigations 28:401–408PubMedCrossRef Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C (2010) Molecular pathways of urothelial development and bladder tumorigenesis. Urologic Oncology: Seminars and Original Investigations 28:401–408PubMedCrossRef
12.
Zurück zum Zitat Dalbagni G, Presti J, Reuter V et al (1993) Genetic alterations in bladder cancer. Lancet 342:469–71PubMedCrossRef Dalbagni G, Presti J, Reuter V et al (1993) Genetic alterations in bladder cancer. Lancet 342:469–71PubMedCrossRef
13.
Zurück zum Zitat Davies BR (2003) Gene products involved in metastasis of bladder cancer. Histol Histopathol 18:969–80PubMed Davies BR (2003) Gene products involved in metastasis of bladder cancer. Histol Histopathol 18:969–80PubMed
14.
Zurück zum Zitat Cordon-Cardo C (2008) Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol Suppl 218:154–65PubMedCrossRef Cordon-Cardo C (2008) Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol Suppl 218:154–65PubMedCrossRef
15.
Zurück zum Zitat Nguyen PL, Swanson PE, Jaszcz W et al (1994) Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol 101:166–76PubMed Nguyen PL, Swanson PE, Jaszcz W et al (1994) Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol 101:166–76PubMed
16.
Zurück zum Zitat Cordon-Cardo C, Zhang ZF, Dalbagni G et al (1997) Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 57:1217–21PubMed Cordon-Cardo C, Zhang ZF, Dalbagni G et al (1997) Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 57:1217–21PubMed
17.
Zurück zum Zitat Billerey C, Chopin D, Aubriot-Lorton MH et al (2001) Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158:1955–9PubMedCrossRef Billerey C, Chopin D, Aubriot-Lorton MH et al (2001) Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158:1955–9PubMedCrossRef
18.
Zurück zum Zitat Hornigold N, Devlin J, Davies AM et al (1999) Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene 18:2657–61PubMedCrossRef Hornigold N, Devlin J, Davies AM et al (1999) Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene 18:2657–61PubMedCrossRef
19.
Zurück zum Zitat Hernandez S, Lopez-Knowles E, Lloreta J et al (2006) Prospective study of FGFR3 mutations as a prognostic factor in non-muscle-invasive urothelial bladder carcinomas. J Clin Oncol 24:3664–71PubMedCrossRef Hernandez S, Lopez-Knowles E, Lloreta J et al (2006) Prospective study of FGFR3 mutations as a prognostic factor in non-muscle-invasive urothelial bladder carcinomas. J Clin Oncol 24:3664–71PubMedCrossRef
20.
Zurück zum Zitat Petraki CD, Sfikas CP (2008) Review. Non-papillary urothelial lesions of the urinary bladder: morphological classification and immunohistochemical markers. In Vivo 22(4):493PubMed Petraki CD, Sfikas CP (2008) Review. Non-papillary urothelial lesions of the urinary bladder: morphological classification and immunohistochemical markers. In Vivo 22(4):493PubMed
21.
Zurück zum Zitat Gönül II, Akyürek N, Dursun A, Küpeli B (2008) Relationship of Ki67, TP53, MDM-2 and BCL-2 expressions with WHO 1973 and WHO/ISUP grades, tumor category and overall patient survival in urothelial tumors of the bladder. Pathol Res Pract 204(10):707–17. doi:10.1016/j.prp.2008.03.011 PubMedCrossRef Gönül II, Akyürek N, Dursun A, Küpeli B (2008) Relationship of Ki67, TP53, MDM-2 and BCL-2 expressions with WHO 1973 and WHO/ISUP grades, tumor category and overall patient survival in urothelial tumors of the bladder. Pathol Res Pract 204(10):707–17. doi:10.​1016/​j.​prp.​2008.​03.​011 PubMedCrossRef
22.
Zurück zum Zitat Christoph F, Müller M, Schostak M, Soong R, Tabiti K, Miller K (2004) Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction. Urology 64(1):157–61PubMedCrossRef Christoph F, Müller M, Schostak M, Soong R, Tabiti K, Miller K (2004) Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction. Urology 64(1):157–61PubMedCrossRef
23.
Zurück zum Zitat Edgecombe A, Nguyen BN, Djordjevic B, Belanger EC, Mai KT (2012) Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia. Appl Immunohistochem Mol Morphol 20(3):264–71PubMedCrossRef Edgecombe A, Nguyen BN, Djordjevic B, Belanger EC, Mai KT (2012) Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia. Appl Immunohistochem Mol Morphol 20(3):264–71PubMedCrossRef
25.
Zurück zum Zitat Yorukoglu K, Tuna B, Dikicioglu E, Duzcan E, Isisag A, Sen S, Mungan U, Kirkali Z (2003) Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder. Virchows Arch 443(6):734–40PubMedCrossRef Yorukoglu K, Tuna B, Dikicioglu E, Duzcan E, Isisag A, Sen S, Mungan U, Kirkali Z (2003) Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder. Virchows Arch 443(6):734–40PubMedCrossRef
26.
Zurück zum Zitat Epstein JI (2003) The new World Health Organization/International Society of Urological Pathology (WHO/ISUP) classification for TA, T1 bladder tumors: is it an improvement? Crit Rev Oncol Hematol 47(2):83–9PubMedCrossRef Epstein JI (2003) The new World Health Organization/International Society of Urological Pathology (WHO/ISUP) classification for TA, T1 bladder tumors: is it an improvement? Crit Rev Oncol Hematol 47(2):83–9PubMedCrossRef
27.
Zurück zum Zitat Bostwick DG, Mikuz G (2002) Urothelial papillary (exophytic) neoplasms. Virchows Arch 441(2):109–16PubMedCrossRef Bostwick DG, Mikuz G (2002) Urothelial papillary (exophytic) neoplasms. Virchows Arch 441(2):109–16PubMedCrossRef
28.
Zurück zum Zitat Reid MD, Osunkoya AO, Siddiqui MT, Looney SW (2012) Accuracy of grading of urothelial carcinoma on urine cytology: an analysis of interobserver and intraobserver agreement. Int J Clin Exp Pathol 5(9):882–891PubMed Reid MD, Osunkoya AO, Siddiqui MT, Looney SW (2012) Accuracy of grading of urothelial carcinoma on urine cytology: an analysis of interobserver and intraobserver agreement. Int J Clin Exp Pathol 5(9):882–891PubMed
29.
Zurück zum Zitat Krüger S, Thorns C, Böhle A, Feller AC (2003) Prognostic significance of a grading system considering tumor heterogeneity in muscle-invasive urothelial carcinoma of the urinary bladder. Int Urol Nephrol 35(2):169–73PubMedCrossRef Krüger S, Thorns C, Böhle A, Feller AC (2003) Prognostic significance of a grading system considering tumor heterogeneity in muscle-invasive urothelial carcinoma of the urinary bladder. Int Urol Nephrol 35(2):169–73PubMedCrossRef
30.
Zurück zum Zitat Alsheikh A, Mohamedali Z, Jones E, Masterson J, Gilks CB (2001) Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/International Society of Urologic Pathology. Mod Pathol 14(4):267–72PubMedCrossRef Alsheikh A, Mohamedali Z, Jones E, Masterson J, Gilks CB (2001) Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/International Society of Urologic Pathology. Mod Pathol 14(4):267–72PubMedCrossRef
31.
Zurück zum Zitat Desai S, Lim SD, Jimenez RE, Chun T, Keane TE, McKenney JK, Zavala-Pompa A, Cohen C, Young RH, Amin MB (2000) Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol 13(12):1315–23PubMedCrossRef Desai S, Lim SD, Jimenez RE, Chun T, Keane TE, McKenney JK, Zavala-Pompa A, Cohen C, Young RH, Amin MB (2000) Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol 13(12):1315–23PubMedCrossRef
32.
Zurück zum Zitat Rotem D, Cassel A, Lindenfeld N, Mecz Y, Sova Y, Resnick M, Stein A (2000) Urinary cytokeratin 20 as a marker for transitional cell carcinoma. Eur Urol 37(5):601–4PubMedCrossRef Rotem D, Cassel A, Lindenfeld N, Mecz Y, Sova Y, Resnick M, Stein A (2000) Urinary cytokeratin 20 as a marker for transitional cell carcinoma. Eur Urol 37(5):601–4PubMedCrossRef
33.
Zurück zum Zitat Buchumensky V, Klein A, Zemer R, Kessler OJ, Zimlichman S, Nissenkorn I (1998) Cytokeratin 20: a new marker for early detection of bladder cell carcinoma? J Urol 160(6 Pt 1):1971–4PubMed Buchumensky V, Klein A, Zemer R, Kessler OJ, Zimlichman S, Nissenkorn I (1998) Cytokeratin 20: a new marker for early detection of bladder cell carcinoma? J Urol 160(6 Pt 1):1971–4PubMed
34.
Zurück zum Zitat Harnden P, Eardley I, Joyce AD, Southgate J (1996) Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol 78(6):870–5PubMedCrossRef Harnden P, Eardley I, Joyce AD, Southgate J (1996) Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol 78(6):870–5PubMedCrossRef
Metadaten
Titel
Mixed low- and high-grade papillary urothelial carcinoma: histopathogenetic and clinical significance
verfasst von
Kien T. Mai
Trevor A. Flood
Phillip Williams
Zuzana Kos
Eric C. Belanger
Publikationsdatum
01.10.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 4/2013
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-013-1456-7

Weitere Artikel der Ausgabe 4/2013

Virchows Archiv 4/2013 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …